Samsung Biologics, Target Price Raised to 2.05 Million Won…Revenue Growth Maintained
Hana Financial Investment raised Samsung Biologics' target price to 2.05 million won, maintaining a 'Buy' rating due to sustained revenue growth despite future factory expansion uncertainties.
Key takeaway
"Samsung Biologics, Target Price Raised to 2.05 Million Won…Revenue Growth Maintained" — BullBear's AI rates this story as a bullish (positive) signal for markets, with a market-impact score of 20 out of 100. Hana Financial Investment raised Samsung Biologics' target price to 2.05 million won, maintaining a 'Buy' rating due to sustained revenue growth despite future factory expansion uncertainties. Reported by Maeil Business on April 01, 2026. The call is verified against the actual 24-hour price move on BullBear's public conviction ledger.
Catch the next bull catalyst
Telegram alerts when our AI scores a story 80+/100 impact (~1-3 per day, no spam). Verified 30d hit rate 53.2%.
